Eickenhorst joins EMD Serono as US CMO
This article was originally published in Scrip
EMD Serono, a subsidiary of Merck KGaA, has made Dr Thorsten Eickenhorst US chief medical officer and head of US development. Previously, Dr Eickenhorst served as vice-president of clinical development and medical research at Biogen Idec.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.